CTLA4 and non-small cell lung carcinoma: Moreover, current immunotherapy for NSCLC primarily employs immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 (cytotoxic t lymphocyte-associated protein 4) pathways, demonstrating significant clinical benefits in specific patient populations [12–14].